Publicaties

Schellekens A, Kramer R, Vander Moolen A, Dumondt G, DeJong CA.  2009.  Neurofarmacologie van alcohol, cannabis, opiaten, cocaïne en nicotine. Verslavingsgeneeskunde: Psychofarmacologie, psychiatrie en somatiek.

Batalla A, Crippa JA, Busatto GF, Guimaraes FS, Zuardi AW, Valverde O, Atakan Z, McGuire PK, Bhattacharyya S, Martin-Santos R.  2014.  Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review.. Curr Pharm Des. 20(13):2168-85.

Binelli C, Muñiz A, Sanches S, Ortiz A, Navines R, Egmond E, Udina M, Batalla A, López-Sola C, Crippa JA et al..  2015.  New evidence of heterogeneity in social anxiety disorder: defining two qualitatively different personality profiles taking into account clinical, environmental and genetic factors. Eur Psychiatry. 30(1):160-5.

Kamal RM, van Noorden M, Franzek E.J., Dijkstra BAG, Loonen AJ, DeJong CA.  2016.   The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review. Neuropsychobiology. 73

Schellekens AFA, Vanderschuren L.  2019.  Neurobiologie van verslaving. Handboek Verslaving.

Van de Wijer L, Garcia LP, Hanswijk SI, Rando J, Middelman A, Heine RTer, de Mast Q, Martens GJM, Van der Ven AJAM, Kolk SM et al..  2019.  Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model. Transl Psychiatry. 9(1):84.

Van de Wijer L, Mchaile DN, de Mast Q, Mmbaga BT, Rommelse NNJ, Duinmaijer A, Van der Ven AJAM, Schellekens AFA, Kinabo GD.  2019.  Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study. Lancet HIV. 6(4):e250-e258.